New State Laws Aim to Reduce Medication Prices and Increase Transparency

A growing number of U.S. states are pursuing aggressive measures to reduce prescription drug costs by targeting pharmacy benefit managers (PBMs), the powerful companies that negotiate drug prices and manage prescription benefits on behalf of health insurers, employers, and government health programs.

The effort reflects mounting frustration among lawmakers, patients, and healthcare providers over the high cost of prescription medications in the United States. While drug manufacturers have often been the focus of criticism, attention is increasingly shifting toward PBMs, which play a central role in determining how medications are priced, covered, and reimbursed throughout the healthcare system.

PBMs act as intermediaries between pharmaceutical manufacturers, insurance companies, pharmacies, and consumers. They negotiate discounts and rebates with drugmakers, create lists of approved medications known as formularies, and determine reimbursement rates paid to pharmacies. Supporters argue that PBMs help reduce costs through bulk negotiations, while critics contend that the system lacks transparency and may contribute to higher prices for patients.

Several states have introduced or expanded legislation aimed at increasing oversight of PBM operations. These measures include requirements for greater transparency regarding rebates and fees, restrictions on certain pricing practices, and new rules governing relationships between PBMs and pharmacies.

Among the most controversial practices under scrutiny is “spread pricing,” in which a PBM charges a health plan more for a medication than it pays the pharmacy dispensing the drug and retains the difference as profit. Critics argue that the practice can inflate healthcare costs and reduce savings that might otherwise reach consumers.

State officials have also expressed concerns about the growing consolidation within the industry. A small number of large PBMs now control a significant share of the U.S. prescription drug market, leading some policymakers to question whether limited competition contributes to higher prices and reduced consumer choice.

Independent pharmacies have been among the strongest advocates for reform. Many pharmacy owners argue that PBM reimbursement policies have placed severe financial pressure on smaller businesses, particularly in rural communities where pharmacies often serve as critical healthcare providers. Industry groups say some pharmacies have been forced to close because reimbursement rates fail to cover operating costs.

Patient advocacy organizations have also joined calls for reform, arguing that consumers frequently do not benefit from the rebates negotiated between PBMs and drug manufacturers. Critics contend that despite substantial discounts being negotiated behind the scenes, many patients continue to face high out-of-pocket expenses at the pharmacy counter.

The PBM industry rejects claims that it is primarily responsible for rising drug costs. Industry representatives argue that pharmaceutical manufacturers set the initial prices of medications and maintain that PBMs help reduce spending by negotiating lower rates and encouraging competition among drugmakers.

Federal regulators have also taken a closer look at PBM practices. Recent congressional hearings and investigations have examined whether current business models contribute to higher healthcare spending and whether additional transparency requirements are necessary. Some lawmakers have proposed nationwide reforms that would complement actions already being taken at the state level.

Healthcare economists note that the prescription drug supply chain is highly complex, making it difficult to identify a single source of rising costs. However, many experts agree that increasing transparency throughout the system could help policymakers better understand how money flows between manufacturers, insurers, PBMs, pharmacies, and consumers.

The push for reform comes as Americans continue to cite healthcare affordability as one of their top economic concerns. Prescription medications are often among the most significant out-of-pocket expenses faced by patients, particularly those managing chronic conditions such as diabetes, heart disease, and cancer.

Supporters of the state initiatives argue that stronger oversight of PBMs could lead to more competitive pricing and lower costs for consumers. Opponents caution that poorly designed regulations could disrupt existing negotiations and potentially increase healthcare spending if savings generated through PBMs are reduced.

As state legislatures continue debating new rules and regulators expand their investigations, the battle over prescription drug pricing is likely to remain a major issue in healthcare policy. The outcome could reshape how medications are priced and delivered across the United States, affecting millions of patients, pharmacies, insurers, and pharmaceutical companies.